Nine-year data show sustained benefit of nivolumab in patients with high-risk resected melanoma. Lawrence L. Cancer 2026;132:e70234.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lawrence L. Nine-year data show sustained benefit of nivolumab in patients with high-risk resected melanoma. Cancer 2026;132:e70234.
PMID: 41636351